학술논문
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
Document Type
article
Author
Ramireddy Bommireddy; Shannon Stone; Noopur Bhatnagar; Pratima Kumari; Luis E. Munoz; Judy Oh; Ki-Hye Kim; Jameson T. L. Berry; Kristen M. Jacobsen; Lahcen Jaafar; Swe-Htet Naing; Allison N. Blackerby; Tori Van der Gaag; Chloe N. Wright; Lilin Lai; Christopher D. Pack; Sampath Ramachandiran; Mehul S. Suthar; Sang-Moo Kang; Mukesh Kumar; Shaker J. C. Reddy; Periasamy Selvaraj
Source
Vaccines, Vol 10, Iss 6, p 944 (2022)
Subject
Language
English
ISSN
10060944
2076-393X
2076-393X
Abstract
Several approaches have produced an effective vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since millions of people are exposed to influenza virus and SARS-CoV-2, it is of great interest to develop a two-in-one vaccine that will be able to protect against infection of both viruses. We have developed a hybrid vaccine for SARS-CoV-2 and influenza viruses using influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 RBD fused to GM-CSF as an adjuvant. GPI-RBD-GM-CSF fusion protein was expressed in CHO-S cells, purified and incorporated onto influenza VLPs to develop the hybrid vaccine. Our results show that the hybrid vaccine induced a strong antibody response and protected mice from both influenza virus and mouse-adapted SARS-CoV-2 challenges, with vaccinated mice having significantly lower lung viral titers compared to naive mice. These results suggest that a hybrid vaccine strategy is a promising approach for developing multivalent vaccines to prevent influenza A and SARS-CoV-2 infections.